Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-01-25
2011-01-25
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07875589
ABSTRACT:
The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease.
REFERENCES:
patent: 6022859 (2000-02-01), Kiessling et al.
patent: 6780971 (2004-08-01), Wolozin et al.
patent: 2005/0013824 (2005-01-01), Van Noort et al.
patent: 2010/0004168 (2010-01-01), Gehlbach et al.
patent: 0764273 (1998-10-01), None
patent: 1288226 (2003-03-01), None
patent: 95/33997 (1995-12-01), None
Rekas 2004 (Journal of Molecular Biology 340:1167-1183).
Lo et al. (1998. Protein Engineering 11:495-500).
Chabas et al., “The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease,” Science, 2001, 294(5547):1731-1735.
Chou et al., “CD4 T-cell epitopes of human alpha B-crystallin,” J Neurosci. Res., 2004, 75(4):516-523.
Dubin et al., “Human alpha B-crystallin gene and preferential promoter function in lens,” Genomics, 1990, 7 (4):594-601.
GenBank Accession No. BT006770, May 13, 2003.
Sotgiu et al., “Alpha B-crystallin is not a dominant peripheral T-cell autoantigen in multiple sclerosis amongst Sardinians,” Eur. J Neurol., 2003, 10(5):583-586.
Thoua et al., “Encephalitogenic and immunogenic potential of the stress protein alphaB-crystallin in Biozzi ABH (H-2A(g7)) mice,” J Neuroimmunol., 2000, 104(1):47-57.
Van Stipdonk et al., “T- and B-cell nonresponsiveness to self-alphaB-crystallin in SJL mice prevents the induction of experimental allergic encephalomyelitis,” Cell Immunol., 2000, 204(2):128-134.
Van Stipdonk et al., “Tolerance controls encephalitogenicity of alphaB-crystallin in the Lewis rat,” J Neuroimmunol., 2000, 103(2):103-111.
Van Veen et al., “[Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype,” Neurology, 2003, 61:1245-1249.
Johnson, K. P.; et al., “Extended use of glatiramer acetate (Copaxone) is well tolorated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability”, Neurology, 1998, 50:701-708.
Li, David Wan-Cheng; et al., “Calcium-activated RAF/MEK/ERK Signaling Pathway Mediates p53-dependent Apoptosis and is Abrogated by alphaB-Crystallin through Inhibition of RAS Activation”, Molecular Biology of the Cell, Sep. 2005, 16:4437-4453.
Moss, Ronald B; et al., “Th1/Th2 cells in inflammatory disease states: therapeutic implications”, Expert Opin. Biol. Ther., 2004, 4(12):1887-1896.
Outeiro, Tiago Fleming; et al., “Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation”, Biochemical and Biophysical Research Communications, 2006, 351:631-638.
Raman, Bakthisaran; et al., “alphaB-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid beta-peptide and beta2-microglobulin”, Biochem. J., 2005, 392:573-581.
Solomon, Beka; et al., “Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide”, PNAS, Jan. 1996, 93:452-455.
Wang, Jiou; et al., “Somatodendritic accumulation of misfolded SOD1-L126Z in motor neurons mediates degeneration: alphaB-crystallin modulates aggregation”, Human Molecular Genetics, 2005, 14(16):2335-2347.
Nagaraj; et al., “Dicarbonyl stress and apoptosis of vascular cells—Prevention by alpha B-crystallin”, Annals of the New York Acacemy of Sciences (2005), pp. 158-165.
Roelofs; et al., “Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis”, Journal of Immunology (2006), 176(11):7021-7027.
Ousman Shalina Sheryl
Robinson William H.
Steinman Lawrence
Bozicevic Field & Francis LLP
Kolker Daniel E
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Alpha B-crystallin as a therapy for rheumatoid arthritis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha B-crystallin as a therapy for rheumatoid arthritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha B-crystallin as a therapy for rheumatoid arthritis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2719497